Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The International Association for the Study of Lung Cancer made the declaration at the outset of a major cancer meeting in Barcelona.
Biomarker was not linked to response rates in two studies of Keytruda for lung cancer.
Selpercatinib shrank tumors in 68% of patients previously treated with chemotherapy.
Half of study participants treated with AMG 510 saw their tumors shrink, and only one experienced disease progression.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.